UPA UPMAG Semaglutide 10mg – GLP-1 Compound peptide for Metabolic & Weight Management
Ozempic, also known by its generic name semaglutide, is a medication primarily used for the treatment of type 2 diabetes.
Semaglutide activates the GLP-1 (glucagon-like peptide-1) receptor, producing enhanced insulin secretion in response to meals, suppressed glucagon output, delayed gastric emptying and reduced appetite signals. The agent is increasingly studied for its long-term effects on fat distribution and cardiometabolic outcomes. UPA Labs Semaglutide 10mg has been formulated as a high-potency GLP-1 receptor agonist for advanced research focused on weight reduction, satiety enhancement and metabolic health. Extensive clinical data show its ability to reduce appetite, slow gastric emptying and improve glycaemic control.